Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency

Valentina Giunchi,Michele Fusaroli,Agnese Cangini,Filomena Fortinguerra,Simona Zito,Andrea Pierantozzi,Carlotta Lunghi,Elisabetta Poluzzi,Francesco Trotta

DOI: https://doi.org/10.1101/2024.05.16.24307469

2024-05-16

Abstract:Aim This study builds upon the environmental risk analysis presented in the 2022 National Report on Medicines Use in Italy by the Italian Medicines Agency and aims to assess the environmental risk posed by medicines in Italy and in its regions. Methods The analysis selected 90 medicines based on three criteria: high utilization, low PNEC, and inclusion or candidacy for the European Watch List. For each medicine, the environmental risk was computed as the ratio between the Predicted Environmental Concentration (PEC) and the Predicted No Effect Concentration (PNEC). PEC was derived following the approach of the Swedish Association of Pharmaceutical Industries and Italian drug utilization data. The risk was classified high if the ratio was greater than 10, and moderate if greater than 1. Results Overall, 13 medicines were identified as posing a high risk, including cardiovascular agents, antibiotics, analgesics, antidepressants, and antiparasitic agents. The high risk was driven by either a very low PNEC (e.g., estradiol and lacidipine), and high utilization (e.g., amoxicillin, ibuprofen, and diclofenac). Regional analysis showed higher risk due to high consumption for azithromycin and ofloxacin in Central and Southern Italy, and for levonorgestrel in Northern Italy. Conclusion This study points to the need of prioritizing targeted sampling in surface waters for medicines estimated at high risk. To prevent and mitigate the risk, a more conscious clinical practice coupled with appropriate waste management are required.

What problem does this paper attempt to address?

This paper aims to assess the environmental impact of pharmaceuticals in Italy, with a particular focus on their pollution in water systems. The study is based on data from the Italian Medicines Agency and analyzes, for the first time, the environmental impact reported in the National Drug Consumption Report for the year 2022. Ninety pharmaceuticals were selected for the study, including those with high usage, low predicted no-effect concentrations (PNEC), or those listed in the European watch list. The results identified 13 pharmaceuticals with high environmental risks, mainly cardiovascular drugs, antibiotics, analgesics, antidepressants, and antiparasitic drugs. The risks associated with these pharmaceuticals were attributed to their high toxicity or high consumption levels. Regional differences may reflect variations in social and prescription habits.

The study suggests that priority should be given to surface water monitoring for high-risk pharmaceuticals, and preventive and mitigation measures should be implemented through more responsible clinical practices and appropriate waste management. Currently, resources for monitoring pharmaceuticals in the environment are both intensive and limited, hence estimation methods are needed to determine substances in need of priority monitoring. The paper also discusses the potential negative environmental impact of pharmaceuticals throughout their entire lifecycle, from design to disposal, emphasizing the need for measures to reduce these effects.